[go: up one dir, main page]

DK0631502T3 - Lymfocytaktivitetsregulering ved hjælp af HLA-peptider - Google Patents

Lymfocytaktivitetsregulering ved hjælp af HLA-peptider

Info

Publication number
DK0631502T3
DK0631502T3 DK93918763T DK93918763T DK0631502T3 DK 0631502 T3 DK0631502 T3 DK 0631502T3 DK 93918763 T DK93918763 T DK 93918763T DK 93918763 T DK93918763 T DK 93918763T DK 0631502 T3 DK0631502 T3 DK 0631502T3
Authority
DK
Denmark
Prior art keywords
peptides
lymphocyte activity
activity regulation
hla peptides
domains
Prior art date
Application number
DK93918763T
Other languages
English (en)
Inventor
Carol A Clayberger
Alan M Krensky
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK0631502T3 publication Critical patent/DK0631502T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70539MHC-molecules, e.g. HLA-molecules
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56977HLA or MHC typing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK93918763T 1992-03-02 1993-02-25 Lymfocytaktivitetsregulering ved hjælp af HLA-peptider DK0631502T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/844,716 US5888512A (en) 1987-01-30 1992-03-02 Lymphocyte activity regulation by HLA peptides
PCT/US1993/001758 WO1993017699A1 (en) 1992-03-02 1993-02-25 Lymphocyte activity regulation by hla peptides

Publications (1)

Publication Number Publication Date
DK0631502T3 true DK0631502T3 (da) 2001-01-02

Family

ID=25293452

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93918763T DK0631502T3 (da) 1992-03-02 1993-02-25 Lymfocytaktivitetsregulering ved hjælp af HLA-peptider

Country Status (12)

Country Link
US (1) US5888512A (da)
EP (1) EP0631502B1 (da)
JP (1) JP2846470B2 (da)
AT (1) ATE196150T1 (da)
AU (1) AU678381B2 (da)
CA (1) CA2131299A1 (da)
DE (1) DE69329379T2 (da)
DK (1) DK0631502T3 (da)
ES (1) ES2150949T3 (da)
GR (1) GR3034964T3 (da)
PT (1) PT631502E (da)
WO (1) WO1993017699A1 (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5723128A (en) * 1987-01-30 1998-03-03 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides
US7011834B1 (en) 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US5639458A (en) * 1987-03-20 1997-06-17 Regents Of The University Of California Class I MHC modulation of surface receptor activity
US5843156A (en) * 1988-08-24 1998-12-01 Endoluminal Therapeutics, Inc. Local polymeric gel cellular therapy
JPH09508617A (ja) * 1993-11-10 1997-09-02 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 表面膜タンパク質および免疫応答に対するそれらの影響
US5977300A (en) * 1994-06-03 1999-11-02 Ludwig Institute Of Cancer Research Isolated nonapeptide which bind to HLA-B44 molecules and the uses thereof
CA2210812C (en) * 1995-01-16 2009-09-01 Nicholas Manolios T-cell affecting peptides
US6162434A (en) 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
AU1823697A (en) * 1996-01-02 1997-07-28 Board Of Trustees Of The Leland Stanford Junior University Interaction of hla proteins with members of the hsp70 family of proteins
US6436903B1 (en) 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
EP0950065B1 (de) * 1996-09-18 2003-02-19 Gerhild Wildner Peptide als diagnostikum und therapeutikum für autoimmunerkrankungen
EP1027073A2 (en) * 1996-11-19 2000-08-16 Sangstat Medical Corporation Enhanced effects for hapten conjugated therapeutics
PL336302A1 (en) * 1997-04-11 2000-06-19 Sangstat Medical Corp Cytomodulating lypophylic peptides useful in moudulating the immune system and inhibiting inflammations
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
CN1441676B (zh) 2000-03-31 2012-08-22 普渡研究基金会 用配体-免疫原缀合物治疗的方法
US7094413B2 (en) 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
EP1982992B1 (en) 2006-02-07 2010-10-27 NEC Corporation Hla-binding peptide, precursor thereof, dna fragment encoding the same and recombinant vector
TW200745163A (en) * 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
GB0609121D0 (en) 2006-05-09 2006-06-21 Univ Birmingham Peptide Therapy
JPWO2008044567A1 (ja) 2006-10-12 2010-02-12 日本電気株式会社 Hla結合性ペプチド、その前駆体、それをコードするdna断片および組み換えベクター
ES2425486T3 (es) * 2007-05-09 2013-10-15 Circassia Limited Análisis de pronóstico para determinar la respuesta de células T a antígenos HLA y uso del mismo en el campo del trasplante de tejidos
MX2010001363A (es) * 2007-08-09 2010-03-09 Syntonix Pharmaceuticals Inc Peptidos inmunomoduladores.
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US5202424A (en) * 1984-03-19 1993-04-13 The Rockefeller University Mesangial cell-derived receptors for advanced glycosylation endproducts and uses thereof
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
WO1988005784A1 (en) * 1987-01-30 1988-08-11 The Board Of Trustees Of The Leland Stanford Junio Lymphocyte inhibition by hla peptides
EP0400077A4 (en) * 1988-02-12 1990-12-27 The Regents Of The University Of California Use of synthetic peptides to generate and manipulate cellular immunity
WO1990010016A1 (en) * 1989-03-03 1990-09-07 The Regents Of The University Of California Class i mhc modulation of surface receptor activity
US5073540A (en) * 1989-05-15 1991-12-17 Receptron Composite binding site drugs
CA2081582A1 (en) * 1991-11-05 1993-05-06 Teodorica Bugawan Methods and reagents for hla class i dna typing

Also Published As

Publication number Publication date
CA2131299A1 (en) 1993-09-16
AU4807893A (en) 1993-10-05
ES2150949T3 (es) 2000-12-16
JP2846470B2 (ja) 1999-01-13
WO1993017699A1 (en) 1993-09-16
EP0631502A1 (en) 1995-01-04
DE69329379D1 (de) 2000-10-12
JPH08504168A (ja) 1996-05-07
AU678381B2 (en) 1997-05-29
ATE196150T1 (de) 2000-09-15
EP0631502A4 (en) 1996-07-24
EP0631502B1 (en) 2000-09-06
DE69329379T2 (de) 2001-03-29
US5888512A (en) 1999-03-30
GR3034964T3 (en) 2001-02-28
PT631502E (pt) 2001-03-30

Similar Documents

Publication Publication Date Title
DK0631502T3 (da) Lymfocytaktivitetsregulering ved hjælp af HLA-peptider
EP0753005A4 (en) REGULATING THE ACTIVITY OF CYTOTOXIC T-CELL LYMPHOCYTES WITH MHC CLASS I PEPTIDES
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
DK0668772T3 (da) Specifik immunsystemmodulering
DE59009034D1 (de) Desodorierende kosmetische mittel.
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
DE3854300D1 (de) Lymphocyteninhibierung durch hla-peptide.
BR9406652A (pt) Composição
AU1694392A (en) Determination of motifs of peptides on mhc molecules
DK289285D0 (da) Thymopentin analoge
EP0637249A4 (en) SUPPRESSION OF PROLIFERATIVE REACTION AND PROVISION OF TOLERANCE USING CLASS II MHC POLYMORPHIC ALLOPEPTIDES.
FI953093A0 (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
NO970803L (no) Fremgangsmåte for identifisering av forbindelser egnet for behandling av autoimmune sykdommer
ATE248914T1 (de) Allogenes vakzin und synthesemethode für selbiges
DE69929683D1 (de) Antisense modulierung von lfa-3
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
ATE102038T1 (de) Eliminierung von aktivierten lymphozyten.
MY131097A (en) Pharmaceutical compositions comprising interleukin-2
DK0597043T3 (da) Porcine adipocytantigener og deres anvendelse til immunologisk bekæmpelse af fedt
ITMI910013A1 (it) Dispositivo di vincolo, per parti di viadotti e simili
Schauenstein et al. STUDIES ON THE COMPLEMENT RECEPTOR OF CHICKEN SPLEEN CELLS
UA42900A1 (uk) Пристрій для підводної витяжки хребта
IT7922481U1 (it) Dispositivo per l'attacco rapido e la bilanciatura di saliscendi per lampadari.
IT8320622V0 (it) Dispositivo di serraggio perestremita' libere di cavi, funi e simili.